NCT03865212View on ClinicalTrials.gov

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

January 20, 2027

Study Completion Date

January 20, 2027

Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Choroid MelanomaMetastatic MelanomaMetastatic Mucosal MelanomaMetastatic Uveal MelanomaPathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Unresectable Melanoma
Interventions
DRUG

Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1

Given IT and IV

Trial Locations (2)

55905

Mayo Clinic in Rochester, Rochester

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER